Latest News - Verbund AG

Top Corporates Hub

Verbund AG

OEW | VIE | Austria
702
-51
Rank
$27.61B
Market Cap
$8.86B
-$ 2.43B
-21.52%
Revenue
$3.10B
-$ 0.9B
-22.5%
Earnings
4K
-0.1K
-1.47%
Employees
Edwards Lifesciences Has Everything Investors Want Except Value

27.05.2026 10:32

Edwards Lifesciences remains a high-quality business with a wide economic moat , but the stock is still overvalued. Click here to read more on the EW stock.

Read More

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer

18.05.2026 06:00

SANTA CLARA, Calif., May 18, 2026--VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer.

Read More

Edwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft Earnings

13.05.2026 10:24

Soft earnings didn't appear to concern Edwards Lifesciences Corporation's ( NYSE:EW ) shareholders over the last week...

Read More

Boston Scientific: Poised To Rebound With The Healthcare Sector, But When?

11.05.2026 16:30

Boston Scientific Corporation outlook: EP share loss vs PFA leadership, Watchman & neuromod growth, improving margins and low valuation. Click for more on BSX.

Read More

Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise

11.05.2026 13:13

Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. A copy of the letter is available to download here. In Q1 2026, the Artisan Mid Cap Fund reported negative absolute returns but slightly outperformed the Russell Midcap® Growth Index. The market favored lower volatility and income-oriented equities, […]

Read More

Edwards names Theodora Mistras as CFO

05.05.2026 09:36

Mistras, who joins the heart valve company after two years as CFO at pharmaceutical firm Viatris, also brings investment banking experience.

Read More

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue

02.05.2026 15:50

CHICAGO, May 02, 2026--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting.

Read More

Global's Undervalued Small Caps With Insider Actions For May 2026

01.05.2026 09:39

As global markets navigate a complex landscape marked by record highs in major U.S. stock indexes, driven by robust economic data and AI-linked stocks, small-cap companies are capturing investor interest amid resilient consumer demand and evolving geopolitical tensions. In this environment, identifying promising small-cap stocks involves considering factors such as strong earnings potential and strategic insider actions that align with broader market trends.

Read More

Barclays Lifts PT on Edwards Lifesciences Corporation (EW) Following Q1 Earnings

01.05.2026 08:00

Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical device stocks to invest in right now. Barclays raised the price target on Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104 on April 27, reaffirming an Overweight rating on the shares. The rating update came after the company’s fiscal Q1 earnings, with the firm telling […]

Read More

How The Edwards Lifesciences (EW) Investment Story Is Shifting As Views On Growth Diverge

30.04.2026 02:07

Edwards Lifesciences just saw its modeled fair value edge from US$96.93 to US$96.96, a tiny move that still reflects fresh thinking about where the shares might reasonably trade. That small adjustment comes as research houses pull in different directions, with some lifting price targets by US$1 to US$6 and others trimming them by as much as US$13, all circling around questions of execution, growth, and risk. As you read on, you will see how to interpret these shifting targets and keep up with...

Read More

Artisan Global Opportunities Fund Q1 2026 Portfolio Activity

29.04.2026 11:13

During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox.

Read More

Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

28.04.2026 11:05

IRVINE, Calif., April 28, 2026--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026.

Read More

Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

28.04.2026 11:05

IRVINE, Calif., April 28, 2026--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026.

Read More

Medtronic: Expectations Are Low And That's The Opportunity

27.04.2026 15:02

Medtronic is rated a Buy, seeing limited downside and gradual upside from consistent execution and incremental margin gains. Read more on MDT stock here.

Read More

Edwards Lifesciences raises FY26 guidance following strong Q1

24.04.2026 14:25

Edwards Lifesciences revealed that its Q1 2026 performance was better than expected, prompting it to uplift its previous FY26 outlook.

Read More

Edwards Lifesciences Stock Surges On Heart Valve Devices Growth

24.04.2026 12:50

Edwards Lifesciences shares rise after Q1 earnings beat, with strong valve therapy growth and updated 2026 outlook amid mixed analyst views.

Read More

Edwards raises 2026 forecast as TAVR sales surge

24.04.2026 12:34

The stronger outlook follows mixed results from other major medical device makers in the latest quarter, after both Abbott and Boston Scientific cut their full-year guidance.

Read More

Evercore ISI Group Maintains Outperform on Edwards Lifesciences, Raises Price Target to $93

24.04.2026 12:26

Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $92 to $93.

Read More

Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $90

24.04.2026 11:38

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $89 to $90.

Read More